Evolving Care in B-ALL: From Questions to Answers on the Role of CD19 Bispecific T-Cell Engagers

Please visit answersincme.com/AXB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Bijal Shah, MD, MS. In this activity, an expert in oncology discusses B-cell acute lymphoblastic leukemia. Upon completion of this activity, participants should be better able to: Describe the rationale for the development of novel dual CD19 x CD3-targeting bispecific antibodies for patients with relapsed/refractory; B-cell acute lymphoblastic leukemia (R/R B-ALL); Discuss the safety profiles of available and emerging CD19 x CD3-targeting bispecific antibodies; and Design treatment plans for patients with R/R B-ALL that optimize the current and future use of CD19 x CD3-targeting bispecific antibodies.